TY - JOUR
T1 - Current aspects of the quality of head and neck cancer care–survey of the Scandinavian Society for Head and Neck Oncology
AU - Ilmarinen, Taru
AU - Bratland, Åse
AU - Tøndel, Hanne
AU - Guðjónsson, Arnar
AU - Gebre-Medhin, Maria
AU - Palmgren, Björn
AU - Mäenpää, Hanna
AU - Bjørndal, Kristine
AU - Grau Eriksen, Jesper
N1 - Publisher Copyright:
© 2024 Acta Oto-Laryngologica AB (Ltd).
PY - 2024
Y1 - 2024
N2 - Background: All Nordic countries have national cancer registries collecting data on head and neck cancer (HNC) incidence and survival. However, there is a lack of consensus on how other quality aspects should be monitored. Aims: We conducted a web-based survey to find opportunities for quality control and improvement. Methods: A web-based survey was sent to one otorhinolaryngology–head and neck (ORL–HN) surgeon, and one oncologist at each Nordic university hospital treating HNC. In total, 42 responses from all 21 university hospitals were included. Results: In over half of the university hospitals, an oncologist, an ORL—HN surgeon, a pathologist, a radiologist, and a specialized nurse was always present at the multidisciplinary tumor board (MTB) meeting. Of 42 respondents 35 (83%) agreed that treatment delays were systematically recorded for each patient. Eleven of 21 (52%) oncologists agreed that side-effects of (chemo)radiotherapy were systematically recorded. Less than half of the respondents agreed that complications of surgery, and post-treatment quality of life (QOL) were systematically recorded. Conclusions: In the Nordic countries, the importance of HNC treatment timelines is well acknowledged. There is a lack of consensus on the composition of MTB meeting, and how treatment-related morbidity should be monitored outside clinical trials.
AB - Background: All Nordic countries have national cancer registries collecting data on head and neck cancer (HNC) incidence and survival. However, there is a lack of consensus on how other quality aspects should be monitored. Aims: We conducted a web-based survey to find opportunities for quality control and improvement. Methods: A web-based survey was sent to one otorhinolaryngology–head and neck (ORL–HN) surgeon, and one oncologist at each Nordic university hospital treating HNC. In total, 42 responses from all 21 university hospitals were included. Results: In over half of the university hospitals, an oncologist, an ORL—HN surgeon, a pathologist, a radiologist, and a specialized nurse was always present at the multidisciplinary tumor board (MTB) meeting. Of 42 respondents 35 (83%) agreed that treatment delays were systematically recorded for each patient. Eleven of 21 (52%) oncologists agreed that side-effects of (chemo)radiotherapy were systematically recorded. Less than half of the respondents agreed that complications of surgery, and post-treatment quality of life (QOL) were systematically recorded. Conclusions: In the Nordic countries, the importance of HNC treatment timelines is well acknowledged. There is a lack of consensus on the composition of MTB meeting, and how treatment-related morbidity should be monitored outside clinical trials.
KW - Head and neck cancer
KW - multidisciplinary tumor board
KW - quality indicators
KW - treatment delay
KW - 3125 Otorhinolaryngology, ophthalmology
U2 - 10.1080/00016489.2024.2386097
DO - 10.1080/00016489.2024.2386097
M3 - Article
AN - SCOPUS:85200680863
SN - 0001-6489
JO - Acta Oto-Laryngologica
JF - Acta Oto-Laryngologica
ER -